Showing results (1521-1530 of 3,105) with videos related to

Sort By:
Pageof 311
Drug Safety|July 18, 2026
Ponatinib Safety Profile: An Analysis of 10 Years of Real-World ExperienceElias Jabbour, Fausto Castagnetti, Mouna Bardey-Kanaan, et al.
Drug Safety|July 15, 2026
Augmenting Medical Judgment in Signal Confirmation: Design Considerations for an AI-Enabled Causality Assessment FrameworkTarek A Hammad, Justine Rochon, Salman Afsar, et al.
Drug Safety|July 23, 2026
Transient Oral Corticosteroid Use and Acute Upper Gastrointestinal Bleeding in Mild-to-Moderate Asthma: A Case-Crossover StudyJiaying Li, Pierre Ernst, Samy Suissa
Drug Safety|August 10, 2026
Optimising Pharmacovigilance Efficiency with MLIT (Machine Learning for Intelligent Triage): A Tool for Statistical Safety AlertsLuciano Ciccarelli, Olivia Mahaux, Christie Roshan, et al.
Drug Safety|August 18, 2026
Antiemetic Combination Use During the First Trimester and Adverse Circulatory Outcomes in Newborn Infants: A Data-Mining AnalysisThuy N Thai, Judith C Maro, Joshua Brown, et al.
Drug Safety|September 6, 2026
Sodium Glucose Co-Transporter 2 Inhibitors and Ventricular Arrhythmias in Patients with Type 2 Diabetes: A Systematic Review of Observational StudiesWang-Choi Tang, Wanning Wang, Antonios Douros, et al.
Drug Safety|October 1, 2026
The Value of Time-to-Onset for Signal Validation: Experience from the Reporting of COVID-19 Vaccines and Glomerular Diseases in VigiBaseAnnette Rudolph, Monica Tarapues, Oskar Gauffin, et al.
Drug Safety|October 14, 2026
Current Pharmacovigilance Outsourcing Practices in Arab CountriesIbrahim Abdeldayem, Thamir M Alshammari, Karine Palin
Drug Safety|August 12, 2003
Safety and pharmacology of oseltamivir in clinical useRegina Dutkowski, Bharat Thakrar, Enrico Froehlich, et al.
Drug Safety|August 12, 2003
Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significanceGordon S Francis, Yves Grumser, Enrica Alteri, et al.
Pageof 311